Guilford Street Laboratories
Guilford Street Laboratories is a UCL spin-out dedicated to advancing research through machine learning-driven mass spectrometry. They focus on delivering precise biomarker assays for early disease diagnosis, drug discovery, clinical trials, and personalized medicine, with a mission to revolutionize healthcare diagnostics and patient care.
Industries
Nr. of Employees
small (1-50)
Guilford Street Laboratories
Products
Multiplexed targeted biomarker panels (proteins, lipids, metabolites)
Multiplexed targeted panels for simultaneous quantitation of multiple protein, lipid, or metabolite biomarkers to support validation, diagnostics, and monitoring applications.
Mass spectrometry-based anti-drug antibody profiling platform
A mass spectrometry approach to quantify and subtype antibody responses (including subclass and isotype) to enzyme replacement therapies and viral vector gene therapies to inform clinical decision-making.
Multiplexed targeted biomarker panels (proteins, lipids, metabolites)
Multiplexed targeted panels for simultaneous quantitation of multiple protein, lipid, or metabolite biomarkers to support validation, diagnostics, and monitoring applications.
Mass spectrometry-based anti-drug antibody profiling platform
A mass spectrometry approach to quantify and subtype antibody responses (including subclass and isotype) to enzyme replacement therapies and viral vector gene therapies to inform clinical decision-making.
Services
Two-phase proteomic service offering untargeted discovery followed by high-throughput targeted confirmation and multiplexed targeted proteomic panels for biomarker validation and clinical translation.
Targeted lipid analysis including lysosomal lipid analysis and neurolipid profiling to support diagnosis and monitoring of lysosomal storage disorders, cardiovascular and neurological diseases.
Customisable metabolite assay development and execution including bile acid profiling and amino acid analysis, with feasibility consultation and bespoke assay development.
Mass spectrometry-based immune response profiling to quantify antibody subclass and isotype against protein therapeutics and gene therapy vectors for research and clinical monitoring.
Services to support clinical implementation of assays including regulated assay validation, integration of automated workflows, and development of digital reporting tools to enable clinical use and rapid turnaround.
Two-phase proteomic service offering untargeted discovery followed by high-throughput targeted confirmation and multiplexed targeted proteomic panels for biomarker validation and clinical translation.
Targeted lipid analysis including lysosomal lipid analysis and neurolipid profiling to support diagnosis and monitoring of lysosomal storage disorders, cardiovascular and neurological diseases.
Customisable metabolite assay development and execution including bile acid profiling and amino acid analysis, with feasibility consultation and bespoke assay development.
Mass spectrometry-based immune response profiling to quantify antibody subclass and isotype against protein therapeutics and gene therapy vectors for research and clinical monitoring.
Services to support clinical implementation of assays including regulated assay validation, integration of automated workflows, and development of digital reporting tools to enable clinical use and rapid turnaround.
Expertise Areas
- Biomarker discovery and validation
- Targeted proteomics
- Untargeted proteomics
- Lipidomics
Key Technologies
- Mass spectrometry
- Targeted proteomics
- Untargeted proteomics
- Lipidomics
News & Updates
Guilford Street Laboratories received a grant from Chiesi Limited to support the clinical implementation of their ImmunoTADA platform, a mass spectrometry-based system for immune response profiling in rare disease management.
Research on urinary biomarker panels for Alzheimer's diagnosis using targeted proteomics and machine learning.
Study on immune response to Omicron variant of SARS-CoV-2.
Research on plasma proteomic signatures related to COVID-19 symptoms.
Development of a urine assay for Fabry disease monitoring.
Research on biomarkers for hypertrophic cardiomyopathy.
Guilford Street Laboratories received a grant from Chiesi Limited to support the clinical implementation of their ImmunoTADA platform, a mass spectrometry-based system for immune response profiling in rare disease management.
Research on urinary biomarker panels for Alzheimer's diagnosis using targeted proteomics and machine learning.
Study on immune response to Omicron variant of SARS-CoV-2.
Research on plasma proteomic signatures related to COVID-19 symptoms.
Development of a urine assay for Fabry disease monitoring.
Research on biomarkers for hypertrophic cardiomyopathy.